Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Lyme disease is a bacterial infection that can be spread to humans by infected ticks. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025. "VLA15, the Lyme disease vaccine candidate we are co-developing wit
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
The two dominant players in the obesity market will eventually make way for a few more competitors. Among the larger drug companies, Amgen and Roche stand out at the moment, and Wall Street is giving them some credit for it. Amgen’s stock is up over 40% in the past 12 months largely thanks to its obesity program.
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
A decision by the US regulator under the Prescription Drug User Fee Act is anticipated by 15 January 2025.
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Exscientia paid $20m in upfront cash and equity to buy the shares of its development partner GT Apeiron for the CDK7 inhibitor.
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.